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Abstract: We report the synthesis and antimalarial activities of eighteen quinoxaline and 
quinoxaline 1,4-di-N-oxide derivatives, eight of which are completely novel. Compounds 
1a and 2a were the most active against Plasmodium falciparum strains. Structure-activity 
relationships demonstrated the importance of an enone moiety linked to the quinoxaline ring. 
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1. Introduction 
Malaria is an infectious disease with an estimated 219 million cases and 660,000 deaths in 2010. Of 
these cases 86% correspond to children under 5 years old. In 2012, there were a total of 104 countries 
where malaria is considered to be endemic [1]. 
Plasmodium falciparum is the most dangerous form of the malaria parasite and it is responsible for 
a very high percentage of clinical attacks [2]. Artemisinin-based combination therapies (ACTs) are the 
standard treatment against uncomplicated P. falciparum malaria. Nevertheless, resistance to ACTs 
containing dihydroartemisinin has been reported in Pailin (Cambodia) [3] and resistance to pyrethroids 
(used as insecticides) has been detected in 64 countries around the World [1]. Other antimalarial drugs, 
such as chloroquine or mefloquine, are not effective enough [4]. FCR-3 P. falciparum is a 
chloroquine-resistant strain, but sensitive to pyrimethamine and sulfadoxine [5]. 
Over the last years, our group has been working on the development and synthesis of new 
quinoxaline derivatives. As a result of this line of research, the activities of quinoxaline 1,4-di-N-oxide 
derivatives against Mycobacterium tuberculosis [6–13], Trypanosoma cruzi [14,15], Leishmania 
amazonensis [16], L. infantum [17], P. falciparum [16–23] and different tumor cells [24–26] have been 
reported. The presence of two N-oxides is associated with a significant increase in some biological 
properties, such as anticancer [27] or antioxidant [28] activity. On the other hand, some reduced 
quinoxalines showed good antitubercular activity [29]. 
In this article, we report the synthesis and antimalarial activity of some quinoxaline analogs of 
chalcones and other compounds derived from them (Figure 1). Chalcones or 1,3-diaryl-2-propen-1-
ones are ,-unsaturated ketones with a large number of biological activities [30]. Different chalcones have 
been reported as anti-inflammatory [31], anticancer [32], antitubercular [33,34] or antimalarial [34–38] 
agents. With regard to antiplasmodial activity, previous structure-activity relationship studies found 
that the enone linker [38] and its trans-configuration [39] are essential in active chalcones. 
Some of the compounds belonging to this study were previously tested against L. amazonensis [40] 
(series 1), T. cruzi and L. peruviana [41] (series 3) and as cytotoxic agents [42] (compound 1a) and 
anti-inflammatory/antioxidant [28,43] agents (series 1, 3 and 7). According to the structure-activity 
relationships, these reports affirm that compounds in series 3 have better antioxidant activity than their 
analogs in series 1 due to the fact that the former group of molecules lacks the N-oxide groups [28]. On 
the other hand, compounds 1d and 3d have an interesting activity against different Leishmania strains, 
so the activity is associated with R6/R7 = Me/Me substitution [40,41]. Compound 1a stands out as both 
a good anti-inflammatory and cytotoxic agent [42,43]. 
With the aim of expanding the SAR study of these chalcone analogs and obtaining new compounds 
with improved antimalarial activity, we describe herein the synthesis and the relationships between 
structure and antiplasmodial activity against the FCR-3 P. falciparum strain of eighteen quinoxaline 
and quinoxaline 1,4-di-N-oxide derivatives. 
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Figure 1. (a) Design of quinoxaline derivatives as potential antimalarial drugs.  
(b) Examples of two numbered compounds obtained in this synthesis. 
 
2. Results and Discussion 
2.1. Chemistry 
Synthesis of compounds in series 1, 3 and 7 were previously reported [25,40]. Benzofuroxans I 
with Ra/Rb = H/H, H/Cl and H/OMe are commercially available. Benzofuroxan with Ra/Rb = Me/Me 
was synthesized by an oxidative cyclization of 4,5-dimethyl-2-nitroaniline according to a previously 
described method [44]. 
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Scheme 1 shows the entire synthetic route for obtaining compounds 1a–d, 2a and 3a, 3c and their 
cyclopropyl derivatives 4a–d, 5a and 6a, 6c. The starting reagents used, quinoxaline 1,4-di-N-oxides 
II and reduced quinoxalines III, were obtained following previously reported procedures [7,27]. 
Quinoxaline 1,4-di-N-oxides II were synthesized by a classic Beirut reaction [45], using CaCl2 and  
1-aminoethanol as the catalysts [46]. Their reduced analogs III were prepared by reduction of the  
N-oxide groups [27], for which a reaction temperature of 65 °C and a mixture of ethyl acetate/methanol 1:1 
as the solvent [47] was established. 
Scheme 1. Synthesis of series 1, 2, 3, 4, 5 and 6.  
 
Reagents and conditions: (a) NaClO, N,N-DMF, 0 °C; (b) 2,4-pentanedione, CaCl2, 1-aminoethanol; 
(c) Na2S2O4, AcOEt/MeOH 1:1, 65 °C; (d) 3,4,5-trimethoxybenzaldehyde, 3% NaOH/MeOH, −10 °C; 
(e) 2-naphthaldehyde, 5% NaOH/MeOH; (f) 3,4,5-trimethoxybenzaldehyde, 3% NaOH/MeOH, r.t.; 
(g) TBAB, TMSOI, 15% aq. NaOH. 
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As previously described [48], in reactions of monosubstituted benzofuroxans 7-substituted 
quinoxaline 1,4-di-N-oxide derivatives prevail over the 6-isomers. While compound II with R6/R7= 
H/Cl was obtained as the major isomer and was isolated with a subsequent purification [25], 2-acetyl-
7-methoxy-3-methylquinoxaline 1,4-di-N-oxide was obtained as the sole isomer [7]. 
Chalcone analogs 1a–d were synthesized by a previously reported base-catalyzed Claisen-Schmidt 
condensation [49], using 3% NaOH in methanol as the catalyst and establishing an optimum reaction 
temperature of −10 °C [43]. Their reduced analogs 3a, 3c were synthesized using the same catalyst, 
but in this case, the condensation was performed at room temperature, as previously reported [28]. The 
compounds 1a–d and 3a, 3c obtained have been previously described [28,47]. Compound 2a was first 
synthesized according to a previously reported method [50]. It was a spontaneous reaction that gives 
the desired compound in good yield. 
New cyclopropyl derivatives 4a–d, 5a and 6a, 6c were obtained according to a previously reported 
method [51]. These reactions were carried out between compounds 1a–d, 2a and 3a, 3c and 
trimethylsulfoxonium iodide (TMSOI) in the presence of an aqueous solution of NaOH, with 
tetrabutylammonium bromide (TBAB) as a phase transfer catalyst and dichloromethane as the solvent. 
With regard to the reaction mechanism, Corey and Chaykovsky [52] demonstrated that 
trimethylsulfoxonium halides in the presence of a strong base allow the formation of a reactive 
compound named dimethylsulfoxonium methylide (DMSY), commonly known as Corey’s reagent [53]. 
The reaction of DMSY with an ,-unsaturated ketone involves the cyclopropanation of C=C double 
bond [54]. 
As their coupling constant values in the 1H-NMR spectra showed J values ≈ 16 Hz [47], the double 
bond geometries of compounds 1a–d and 3a, 3c were trans, just like the newly synthesized 2a. 
According to previous reports [55,56], the Corey-Chaykovsky reaction with TMSOI ocurrs with 
retention of stereochemistry, giving trans-cyclopropyl derivatives 4a–d, 5a and 6a, 6c [51]. 
Scheme 2 shows the synthetic route for obtaining compounds 7a–d. These chalcone analogs were 
obtained by a microwave-assisted Wittig reaction [28] between 2-formyl-3-methylquinoxaline 1,4-di-
N-oxide derivatives V and a phosphonium ylide VII, both previously synthesized [28,45,57]. 
Scheme 2. Synthesis of series 7 [28].  
 
Reagents and conditions: (a) 2-butanone, morpholine; (b) SeO2, acetonitrile, MW: 5 min, 200 W;  
(c) Br2, acetic acid; (d) PPh3, NaH/H2O, toluene; (e) MeOH, MW: 5 min, 25 W. 
N
O
N+
Ra
Rb
O-
N+
N+
Ra
Rb
O-
O-
N+
N+
Ra
Rb
O-
O-
H
O
a b
O
O
O
O
H
O
O
O
O
Br
O
O
O
O
PPh3
c d
e
N+
N+
Ra
Rb
O
O
O
O
O-
O-
Series 7
7a, 7b, 7c, 7d
IVI
V
VI VII
Ra/Rb: H/H (a); H/Cl (b); H/OMe (c); Me/Me (d)
Molecules 2014, 19 2171 
 
2.2. Biological Results 
In this study, eighteen quinoxaline and quinoxaline 1,4-di-N-oxide derivatives were tested against a 
chloroquine-resistant FCR-3 strain of P. falciparum. All the synthesized compounds and their 
biological activities are shown in Tables 1, 2 and 3. 
Table 1. In vitro activities of chalcone derivatives. 
Compound R6 R7 n R IC50 (M) a SD b 
1a H H 1 3,4,5-trimethoxyphenyl 6.2 1.7 
1b H Cl 1 3,4,5-trimethoxyphenyl 27.3 3.6 
1c H OMe 1 3,4,5-trimethoxyphenyl 31.1 20.4 
1d Me Me 1 3,4,5-trimethoxyphenyl 24.4 14.0 
2a H H 1 naphthyl 5.8 0.8 
3a H H 0 3,4,5-trimethoxyphenyl 21.5 5.3 
3c H OMe 0 3,4,5-trimethoxyphenyl 26.4 0.3 
CQ c - - - - 0.173 0.003 
a IC50, concentration required for inhibiting growth of FCR-3 P. falciparum strain by 50% 
(in M). Mean values of two independent experiments performed in triplicate; b SD, standard 
deviation; c Chloroquine, control. 
Table 2. In vitro activities of cyclopropyl derivatives. 
Compound R6 R7 n R IC50 (M) a SD b 
4a H H 1 3,4,5-trimethoxyphenyl 56.4 6.4 
4b H Cl 1 3,4,5-trimethoxyphenyl 20.1 6.9 
4c H OMe 1 3,4,5-trimethoxyphenyl NA d - 
4d Me Me 1 3,4,5-trimethoxyphenyl NA - 
5a H H 1 naphthyl 62.1 20.0 
6a H H 0 3,4,5-trimethoxyphenyl NA - 
6c H OMe 0 3,4,5-trimethoxyphenyl NA - 
CQ c - - - - 0.173 0.003 
a IC50, concentration required for inhibiting growth of FCR-3 P. falciparum strain by 50% 
(in M). Mean values of two independent experiments performed in triplicate; b SD, 
standard deviation; c Chloroquine, control; d NA, not active. 
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Table 3. In vitro activities of inverted chalcone derivatives. 
Compound R6 R7 IC50 (M) a SD b 
7a H H 29.0 3.5 
7b H Cl 24.2 0.8 
7c H OMe 34.3 2.0 
7d Me Me 24.5 4.7 
CQ c - - 0.173 0.003 
a IC50, concentration required for inhibiting growth of FCR-3 P. falciparum strain by 50% 
(in M). Mean values of two independent experiments performed in triplicate; b SD, standard 
deviation; c Chloroquine, control. 
Almost all the synthesized compounds exhibited some activity against P. falciparum, but none of 
them had better IC50 values than chloroquine itself. Compounds 1a and 2a have been chosen as lead 
compounds with interesting activities against the parasite. Although both leads were chalcone analogs 
with R6/R7 = H/H, compounds 7b and 4b had the best activities among inverted chalcone and 
cyclopropyl derivatives. In these cases, the presence of a halogen atom in position 7 led to an increase 
in the activity. In fact, 4b was the third most active compound of the study. These results coincide with 
previous reports [18], where the most active compounds were those without any substitution on the 
quinoxaline ring and with monosubstitution by an electron withdrawing group. 
Apart from compound 4b, changing the double bond in chalcones (compounds 1a–d, 2a and 3a, 3c) 
for a cyclopropyl structure led to a dramatic drop in the antiplasmodial activity in each case 
(compounds 4a–d, 5a and 6a, 6c). The same trend was noted when comparing cyclopropyl derivatives 
4a–d with their analogs in series 7. 
With regard to series 1 and 7, the inversion of the chalcone did not lead to a change in the 
antimalarial activity, except for compound 1a, whose IC50 was significantly lower than that of the 
others. Therefore, the orientation of the enone moiety does not appear to be a determining factor for 
the antimalarial activity. Finally, only reduced chalcones 3a and 3c showed some interesting activity, 
while reduced cyclopropyl derivatives 6a and 6c were completely inactive. According to previous 
reports [58], a minimum requirement for the antimalarial activity was the oxygenation of N-1 and N-4 
of the quinoxaline ring, because mono and reduced compounds were not active. Nevertheless, in this 
study the presence of N-oxides was not decisive for the synthesized compounds to be active. 
3. Experimental  
3.1. General Information 
All of the synthesized compounds were chemically characterized by thin layer chromatography 
(TLC), melting point, proton nuclear magnetic resonance (1H-NMR), infrared spectroscopy (IR) and 
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elemental microanalyses (CHN). Alugram SIL G/UV254 (0.2 mm layer, Macherey-Nagel GmbH & 
Co. KG., Düren, Germany) was used for TLC, and silica gel 60 (0.040–0.063 mm, Merck, Darmstadt, 
Germany) was used for column chromatography. The 1H-NMR spectra were recorded on a Bruker 400 
Ultrashield instrument (400 MHz, Bruker, Billerica, MA, USA), using TMS as the internal standard 
and DMSO-d6 as the solvent. Chemical shifts are reported in ppm () and coupling constants (J) values 
are given in Hertz (Hz). Signal multiplicities are represented by: s (singlet), d (doublet), t (triplet), q 
(quadruplet), dd (double doublet) and m (multiplet). The IR spectra were recorded on a Thermo 
Nicolet Nexus FTIR (Madison, WI, USA) in KBr pellets. Frequencies () are reported in cm−1 and 
peak intensities are represented by: w (weak), m (medium), s (strong) and vs (very strong). Elemental 
microanalyses were obtained on a CHN-900 Elemental Analyzer (Leco, Tres Cantos, Madrid, Spain) 
from vacuum-dried samples. The analytical results for C, H and N were within ±0.4 of the theoretical 
values, indicating a purity of >95%. All reagents and solvents were purchased from commercial 
sources: E. Merck (Darmstadt, Germany), Panreac Química S.A. (Barcelona, Spain), Sigma-Aldrich 
Química S.A. (Alcobendas, Madrid, Spain), Acros Organics (Janssen Pharmaceuticalaan, Geel, 
Belgium), Scharlau (F.E.R.O.S.A., Barcelona, Spain) and Lancaster (Bischheim-Strasbourg, France). 
3.2. General Procedure of Synthesis 
3.2.1. Synthesis of 3-Methyl-2-[3-(naphth-2-yl-prop-2-enoyl)] quinoxaline 1,4-di-N-oxide Derivatives 
(Series 2) 
The appropriate quinoxaline di-N-oxide II (2-acetyl-3-methylquinoxaline 1,4-di-N-oxide, 3 mmol) 
and 2-naphthaldehyde (3 mmol) were dissolved in methanol (30 mL). 5% NaOH in methanol (10 mL) 
was added dropwise and the reaction mixture was magnetically stirred at room temperature for 15 min, 
until a yellow precipitate appeared. The solid obtained was filtered off and washed with diethyl ether. 
3-Methyl-2-[3-(naphth-2-yl-prop-2-enoyl)] quinoxaline 1,4-di-N-oxide (2a). Yield 57%. mp 184 °C. 
1H-NMR (DMSO-d6)  ppm: 2.40 (s, 3H, CH3); 7.37 (d, 1H, Hb, Jb-a,trans = 16.4 Hz); 7.58 (m, 2H, 
H6+H7); 7.91 (d, 1H, H3'); 8.01 (m, 5H, H4'+H5'+H6'+H7'+H8'); 8.03 (d, 1H, Ha, Ja-b,trans = 16.0 Hz); 8.24 (s, 
1H, H1'); 8.47 (d, 1H, H8, J8–7 = 8.6 Hz); 8.58 (d, 1H, H5, J5–6 = 8.4 Hz). IR (KBr)  cm−1: 3091 (w, 
arC-H); 3055 (w, alkC-H); 3018 (w, C-H); 1675 (m, C=O); 1600 (s, arC=C); 1331 (vs, N-O). Anal. Calc. 
for C22H16N2O3: C = 74.14%, H = 4.53%; N = 7.86%; Found: C = 74.19%, H = 4.40%; N = 7.85%. 
3.2.2. Synthesis of 3-Methyl-2-[2-(3,4,5-trimethoxyphenyl)cyclopropanecarbonyl] quinoxaline 1,4-di-
N-oxide Derivatives (Series 4), 3-Methyl-2-[2-(2-naphthyl)cyclopropanecarbonyl] quinoxaline 1,4-di-
N-oxide Derivatives (Series 5) and 3-Methyl-2-[2-(3,4,5-trimethoxyphenyl)cyclopropanecarbonyl] 
quinoxaline Derivatives (Series 6) 
The appropriate chalcone 1a–d, 2a and 3a, 3c (1 mmol), trimethylsulfoxonium iodide (TMSOI,  
2 mmol) and tetrabutylammonium bromide (TBAB, 0.2 mmol) were dissolved in dichloromethane  
(40 mL) and stirred magnetically at room temperature for 15 min. Then a 15% aqueous solution of 
NaOH (10 mL) was added dropwise and the reaction mixture was stirred magnetically at room 
temperature for 24 h, until the solution turned dark. At this point, excess dichloromethane and water 
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were added to the reaction. The organic phase was extracted, dried with anhydrous Na2SO4, filtered 
and concentrated under reduced pressure. The residue was purified by column chromatography using 
ethyl acetate as the eluent. The desired compounds 4a–d, 5a and 6a, 6c were obtained after 
recrystallization from ethanol.  
3-Methyl-2-[2-(3,4,5-trimethoxyphenyl)cyclopropanecarbonyl] quinoxaline 1,4-di-N-oxide (4a). Yield 
56%. mp 178–179 °C. 1H-NMR (DMSO-d6)  ppm: 1.86 (m, 2H, Hc+Hc'); 2.40 (s, 3H, CH3); 2.78 (m, 
1H, Ha); 2.91 (m, 1H, Hb); 3.59 (s, 3H, p-OCH3); 3.75 (s, 6H, m-OCH3); 6.55 (s, 2H, H2'+H6'); 7.98 (m, 
2H, H6+H7); 8.44 (d, 1H, H8, J8–7 = 8.2 Hz); 8.49 (d, 1H, H5, J5–6 = 8.2 Hz). IR (KBr)  cm−1: 3071 (w, 
arC-H); 2998 and 2965 (w, C-H); 1690 (m, C=O); 1590 (m, arC=C); 1329 (s, N-O); 1128 (s, C-O-C). Anal. 
Calc. for C22H22N2O6: C = 64.37%, H = 5.41%; N = 6.83%; Found: C = 64.08%, H = 5.74%; N = 
6.69%. 
7-Chloro-3-methyl-2-[2-(3,4,5-trimethoxyphenyl)cyclopropanecarbonyl] quinoxaline 1,4-di-N-oxide 
(4b). Yield 9%. mp 143–144 °C. 1H-NMR (DMSO-d6)  ppm: 1.88 (m, 2H, Hc+Hc'); 2.39 (s, 3H, 
CH3); 2.79 (m, 1H, Ha); 2.87 (m, 1H, Hb); 3.60 (s, 3H, p-OCH3); 3.76 (s, 6H, m-OCH3); 6.54 (s, 2H, 
H2'+H6'); 8.01, 8.02 (dd, 1H, H6, J6–8 = 2.3 Hz, J6–5 = 9.2 Hz); 8.42 (d, 1H, H8, J8–6 = 2.2 Hz); 8.48 (d, 
1H, H5, J5–6 = 9.2 Hz). IR (KBr)  cm−1: 3101 (w, arC-H); 2935 (w, C-H); 1695 (m, C=O); 1592 (m, 
arC=C); 1326 (s, N-O); 1128 (s, C-O-C). Anal. Calc. for C22H21N2O6Cl: C = 59.39%, H = 4.77%; N = 
6.30%; Found: C = 59.52%, H = 4.93%; N = 6.15%. 
7-Methoxy-3-methyl-2-[2-(3,4,5-trimethoxyphenyl)cyclopropanecarbonyl] quinoxaline 1,4-di-N-oxide 
(4c). Yield 13%. mp 174–175 °C. 1H-NMR (DMSO-d6)  ppm: 1.84 (m, 2H, Hc+Hc'); 2.37 (s, 3H, 
CH3); 2.79 (m, 1H, Ha); 2.90 (m, 1H, Hb); 3.61 (s, 3H, p-OCH3); 3.77 (s, 6H, m-OCH3); 3.98 (s, 3H,  
7-OCH3); 6.54 (s, 2H, H2'+H6'); 7.58, 7.61 (dd, 1H, H6, J6–8 = 2.8 Hz, J6–5 = 9.5 Hz); 7.74 (d, 1H, H8, 
J8–6 = 2.7 Hz); 8.40 (d, 1H, H5, J5–6 = 9.5 Hz). IR (KBr)  cm−1: 3005 (w, arC-H); 2945 (w, C-H); 1689 
(m, C=O); 1587 (m, arC=C); 1323 (s, N-O); 1120 (m, C-O-C). Anal. Calc. for C23H24N2O7: C = 62.71%, 
H = 5.50%; N = 6.36%; Found: C = 62.55%, H = 5.83%; N = 6.64%. 
3,6,7-Trimethyl-2-[2-(3,4,5-trimethoxyphenyl)cyclopropanecarbonyl] quinoxaline 1,4-di-N-oxide (4d). 
Yield 24%. mp 187–189 °C. 1H-NMR (DMSO-d6)  ppm: 1.84 (m, 2H, Hc+Hc'); 2.37 (s, 3H, CH3); 
2.47–2.51 (m, 6H, 6,7-CH3); 2.76 (m, 1H, Ha); 2.90 (m, 1H, Hb); 3.59 (s, 3H, p-OCH3); 3.75 (s, 6H,  
m-OCH3); 6.54 (s, 2H, H2'+H6'); 8.18 (s, 1H, H8); 8.25 (s, 1H, H5). IR (KBr)  cm−1: 2932 (w, C-H); 
1683 (m, C=O); 1589 (m, arC=C); 1326 (s, N-O); 1132 (s, C-O-C). Anal. Calc. for C24H26N2O6: C = 
65.73%, H = 5.99%; N = 6.39%; Found: C = 65.41%, H = 5.79%; N = 6.40%. 
3-Methyl-2-[2-(2-naphthyl)cyclopropanecarbonyl] quinoxaline 1,4-di-N-oxide (5a). Yield 66%. mp 
176–177 °C. 1H-NMR (DMSO-d6)  ppm: 1.93 (m, 1H, Hc); 1.99 (m, 1H, Hc'); 2.40 (s, 3H, CH3); 3.01 
(m, 2H, Ha+Hb); 7.38 (d, 1H, H3’); 7.47 (m, 2H, H6'+H7'); 7.80 (s, 1H, H1'); 7.85 (m, 3H, H4'+H5'+H8'); 
7.96 (m, 2H, H6+H7); 8.42 (d, 1H, H8, J8–7 = 8.2 Hz); 8.48 (d, 1H, H5, J5–6 = 8.5 Hz). IR (KBr)  cm−1: 
3091 (w, arC-H); 2959 (w, C-H); 1689 (s, C=O); 1597 (w, arC=C); 1328 (s, N-O). Anal. Calc. for 
C23H18N2O3: C = 74.57%, H = 4.91%; N = 7.56%; Found: C = 74.57%, H = 4.90%; N = 7.57%. 
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3-Methyl-2-[2-(3,4,5-trimethoxyphenyl)cyclopropanecarbonyl] quinoxaline (6a). Yield 41%. mp  
155–156 °C. 1H-NMR (DMSO-d6)  ppm: 1.77 (s, 1H, Hc); 1.84 (s, 1H, Hc'); 2.69 (s, 1H, Ha); 2.86 (s, 
3H, CH3); 3.57 (m, 1H, Hb); 3.61 (s, 3H, p-OCH3); 3.77 (s, 6H, m-OCH3); 6.59 (s, 2H, H2'+H6'); 7.88 
(m, 1H, H6); 7.96 (m, 1H, H7); 8.08 (m, 1H, H8); 8.18 (m, 1H, H5). IR (KBr)  cm−1: 2961 and 2935 
(w, C-H); 1679 (s, C=O); 1589 (m, arC=C); 1132 (s, C-O-C). Anal. Calc. for C22H22N2O4: C = 69.81%, 
H = 5.87%; N = 7.40%; Found: C = 69.86%, H = 5.83%; N = 7.40%. 
7-Methoxy-3-methyl-2-[2-(3,4,5-trimethoxyphenyl)cyclopropanecarbonyl] quinoxaline (6c). Yield 
29%. mp 163–164 °C. 1H-NMR (DMSO-d6)  ppm: 1.76 (m, 1H, Hc); 1.84 (m, 1H, Hc'); 2.69 (m, 1H, 
Ha); 2.83 (s, 3H, CH3); 3.58 (m, 1H, Hb); 3.63 (s, 3H, p-OCH3); 3.80 (s, 6H, m-OCH3); 3.96 (s, 3H,  
7-OCH3); 6.60 (s, 2H, H2'+H6'); 7.52 (d, 1H, H8, J8–6 = 2.8 Hz); 7.58, 7.60 (dd, 1H, H6, J6–8 = 2.8 Hz, 
J6–5 = 9.2 Hz); 7.98 (d, 1H, H5, J5–6 = 9.2 Hz). IR (KBr)  cm−1: 2936 (w, C-H); 1680 (s, C=O); 1587 
(m, arC=C); 1130 (s, C-O-C). Anal. Calc. for C23H24N2O5: C = 67.62%, H = 5.93%; N = 6.86%; Found: 
C = 67.23%, H = 6.13%; N = 6.74%. 
3.3. In Vitro Antiplasmodial Drug Assay 
Chloroquine-resistant FCR-3 strain of P. falciparum was cultivated at 37 °C in 5% CO2, 5% O2 in a 
balanced N2 atmosphere environment on RPMI 1640 medium supplemented with gentamicin  
0.1 mg/mL and 10% heat-inactivated A+ human serum, as previously described [59]. The drugs, 
dissolved in dimethyl sulfoxide, were added at final concentrations ranging from 250 to 0.1 M. The 
final DMSO concentration was never greater than 0.1%. In vitro antimalarial activity was measured 
using the [3H]-hypoxanthine (MP Biomedicals, Santa Ana, CA, USA) incorporation assay [60]. Briefly, 
250 L of total culture medium with the diluted drug and the suspension of human red blood cells in 
medium (A+ group, 5% hematocrit) with 1% parasitemia were placed into the wells of 96-well 
microtiter plates. On the third day of the test, radioactivity was assessed. All experiments were 
performed in triplicate. Results were expressed as the concentration resulting in 50% inhibition (IC50), 
which was calculated by a nonlinear regression logistic dose response model. The mean IC50 values 
and standard deviation for each compound was calculated. 
4. Conclusions 
Eighteen quinoxaline and quinoxaline 1,4-di-N-oxide derivatives have been synthesized with the 
aim of studying their antimalarial activity. The SAR study suggested that the chalcone and inverted 
chalcone moieties can act as useful linkers in the search for antimalarial ligands. Moreover, the similar 
activities of series 1, 3 and 7 allow us to affirm that the enone moiety plays an important role in the 
antimalarial activity of these compounds, but not its orientation. Compounds 1a and 2a showed the 
best antiplasmodial activity. In general, the addition of cyclopropyl moiety dramatically reduces the 
biological activity in each case. We are not able to unequivocally confirm that N-oxides are essential 
for the antiplasmodial activity. These results show that further structural modifications may provide 
better antimalarial compounds. 
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